Clear cell sarcoma is an extremely rare soft tissue cancer that develops in deep tissues near tendons and connective tissue sheaths, most often in the arms and legs. It affects roughly 2 to 3 people per million each year, primarily striking young adults between the ages of 20 and 40. Because the tumor cells produce melanin pigment similar to skin cancer cells, it was historically called “melanoma of soft parts,” but it is genetically a completely different disease from melanoma.
Where It Develops in the Body
Clear cell sarcoma has a strong tendency to grow in or around tendons and aponeuroses, the flat sheets of connective tissue that attach muscles to bones. The foot and ankle are the single most common location, though tumors can appear anywhere in the upper or lower extremities. Unlike melanoma, which starts in the skin, clear cell sarcoma arises in deeper tissues and almost never involves the outer skin layer.
Most people notice a slowly enlarging, firm mass that may have been present for months or even years before diagnosis. The tumor often grows without pain initially, which contributes to delayed detection. By the time many patients seek medical attention, the mass has been growing for a considerable period.
The Genetic Driver Behind the Tumor
Nearly all clear cell sarcomas are caused by a specific chromosomal swap in which two genes that don’t normally interact get fused together. The most common version joins a gene on chromosome 22 (EWSR1) with one on chromosome 12 (ATF1), creating a hybrid protein that drives tumor growth. A smaller number of cases involve a fusion between EWSR1 and a different gene called CREB1. These fusions activate pathways that cause the cells to take on melanin-producing characteristics, which is why the tumor looks so much like melanoma under a microscope.
This genetic signature is important for more than academic reasons. It is the single most reliable way to confirm that a tumor is clear cell sarcoma rather than something else, and detecting it has become a routine part of diagnosis.
How It’s Distinguished From Melanoma
Telling clear cell sarcoma apart from metastatic melanoma is one of the most critical challenges in diagnosing this cancer, because the two look strikingly similar under the microscope. Both stain positive for the same melanin-related markers, including S-100 protein (positive in about 64% of cases), HMB-45 (90%), and Melan-A (43%). None of these markers alone can separate the two diseases.
The key difference is genetic. Melanoma frequently carries mutations in a gene called BRAF, while clear cell sarcoma never does. Instead, clear cell sarcoma carries the EWSR1 gene rearrangement described above. Pathologists use a technique called FISH (fluorescence in situ hybridization) to look for this rearrangement, and current recommendations call for FISH testing on any deep soft tissue tumor that shows melanin-producing characteristics but has no obvious connection to a skin melanoma. Getting this distinction right matters enormously because the treatments and expected outcomes are different for each disease.
Signs and Symptoms
The hallmark presentation is a slow-growing lump, usually on a limb, that feels firm and may be attached to deeper structures rather than moving freely under the skin. Some patients experience tenderness or discomfort as the mass enlarges and presses on surrounding tissues, but many report no pain at all in the early stages. The tumor can range from small, walnut-sized nodules to masses several centimeters across by the time of diagnosis.
Clear cell sarcoma has a notable tendency to spread to nearby lymph nodes, which is unusual among soft tissue sarcomas. It can also metastasize to the lungs, bones, and other distant sites, particularly when diagnosis is delayed.
Treatment Options
Surgery with wide removal of the tumor and a margin of healthy tissue remains the primary treatment. For high-grade soft tissue sarcomas like clear cell sarcoma, surgeons aim for margins of at least 1 to 2 centimeters when anatomy allows, though the quality of the tissue barrier at the margin (such as muscle lining or the membrane covering bone) may matter as much as the raw distance. Radiation therapy is sometimes added after surgery to reduce the chance of the tumor returning locally.
When the cancer has spread or cannot be fully removed, systemic treatment becomes necessary, but clear cell sarcoma responds poorly to most standard chemotherapy. The best available data, drawn from a large international review of treated patients, found that doxorubicin-based chemotherapy, the most commonly used regimen, produced a response in only about 12% of patients. Gemcitabine-based regimens fared slightly better at 15%.
The most promising drug identified so far is sunitinib, a targeted therapy that blocks the growth of blood vessels feeding the tumor. In the same international series, sunitinib produced a response in 30% of patients, the highest rate among all agents studied. Based on these results, sunitinib is often recommended as a first-line systemic option when no clinical trial is available.
Why Targeted Therapies Have Been Difficult
Researchers initially had high hopes for drugs targeting a protein called MET, which is overactive in many clear cell sarcomas. Two MET-blocking drugs were tested in clinical trials, but results were disappointing. Tivantinib produced a response in just 1 of 11 patients, with a median time before the cancer progressed again of only 1.9 months. Crizotinib fared somewhat better at keeping the disease stable (about 68% disease control), but only 1 of 28 patients saw their tumor actually shrink, and progression-free survival was 4.3 months. Early-phase trials combining immunotherapy drugs with sunitinib have shown occasional responses, but these have been short-lived. The search for effective systemic therapy remains one of the biggest unmet needs for this cancer.
Prognosis and Survival
Outcomes depend heavily on how far the cancer has spread at the time of diagnosis. A large analysis of U.S. cancer registry data found that patients diagnosed with localized disease, meaning the tumor had not spread beyond its original site, had a 5-year disease-specific survival of 82.4% and a 10-year survival of 68.8%. Those numbers drop sharply with more advanced disease.
Patients diagnosed at a regional stage, where the cancer had spread to nearby tissues or lymph nodes, had a 5-year survival of 44% and a 10-year survival of 32.5%. The outlook for distant metastatic disease is particularly grim: no patients in the registry analysis survived to five years, and only about 7% were alive at two years. Statistical modeling showed that patients with distant-stage disease faced a risk of death more than 22 times higher than those with localized tumors.
These numbers underscore why early detection and complete surgical removal offer the best chance of long-term survival. Because the tumor grows slowly and often without pain, any persistent, unexplained soft tissue mass in the extremities, especially near the foot, ankle, or along a tendon, warrants medical evaluation rather than a wait-and-see approach.